Beclomethasone loaded liposomes enriched with mucin: A suitable approach for the control of skin disorders.

Inflammatory skin disorders are the fourth leading cause of chronic non-fatal conditions, which have a serious impact on the patient quality of life. Due to their treatment with conventional corticosteroids, which often result in poor therapeutic efficacy, relapses and systemic side effects from prolonged therapy, these diseases represent a global burden that negatively impacts the global economy. To avoid these problems and optimize corticosteroid benefits, beclomethasone was loaded into liposome formulations specifically tailored for skin delivery.

A New Hyaluronic Emulgel of Hesperetin for Topical Application-An In Vitro Evaluation.

The present study aimed to formulate and characterize a hesperetin formulation to achieve adequate deposition and retention of hesperetin in the epidermis as a target for some cosmetic/dermatological actions. To derive the final emulgel, various formulations incorporating different proportions of Polysorbate 80 and hyaluronic acid underwent testing through a Box-Behnken experimental design. Nine formulations were created until the targeted emulgel properties were achieved.

Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications.

Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood-brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity's olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability.

American and European legislation on border medical devices.

Introduction: Borderline medical devices are products in a 'gray area,' this means due to their characteristics, they could belong to different 'legal products.' In addition, regulation is a controversial topic and may change depending on the country which may put public health at risk and distort the market.

Areas Covered: This article analyzes how borderline medical devices are managed in the American and the European legislation.

New scenario in the field of medical devices in the European Union: Switzerland and the United Kingdom become third countries.

Objective: To compare the measures taken by the European Union,  Switzerland and the United Kingdom to ensure the continuity of the medical  devices market, complying with the requirements of Regulation  2017/745.

Method: To carry out this work, a review was made of the official websites of  the European Commission, the Spanish Agency for Medicines and Health  Products, the Swiss Agency for Therapeutic Products and the Medicines and  Healthcare Products Regulatory Agency of the United Kingdom. Bibliographic  searches were also conducted on Pubmed and the internet (Google), using  terms such as "withdrawal of the Mutual Recognition Agreement of Swiss  European Union medical device conformity certificates, new UK medical device  regulation", for a period extending from January 2020 to December 2021.